The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients
Primary Purpose
Parkinson, Cognitive Impairment, Upper Extremity Problem
Status
Completed
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
clinical assessment
Sponsored by
About this trial
This is an interventional other trial for Parkinson focused on measuring Parkinson, Cognitive function, Upper extremity
Eligibility Criteria
Inclusion Criteria: Having a diagnosis of Parkinson's Disease. Not having hearing and vision problems. To be able to take the commands required for the manual dexterity tests. Agree to participate in the study. Exclusion Criteria: Having undergone musculoskeletal surgery for the upper extremity. Having vision and hearing problems. Having an additional disease that may affect cognitive tests.
Sites / Locations
- Pamukkale Unıversity
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Other
Arm Label
patient group
healthy group
Arm Description
parkınson patient group
age-gender matched healthy group
Outcomes
Primary Outcome Measures
Modified Hoehn Yahr Scale
Used for clinical staging of Parkinson's disease
Unified Parkinson's Disease Rating Scale
Used for the evaluation of clinical manifestations of Parkinson's disease
Parkinson's Disease Questionnaire-PDQ 39
Used to assess the quality of life of Parkinson's patients
Secondary Outcome Measures
Stroop Test
measures the selective attention ability of individuals
Wechsler Memory Scale-Revised
To assess attention, learning, memory and working memory in individuals aged 16-89
Dexterity Questionnaire-24
To assess manuel dexterity
Nine Hole Peg Test
To assess manuel dexterity
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05872646
Brief Title
The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients
Official Title
The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
February 8, 2018 (Actual)
Primary Completion Date
March 10, 2023 (Actual)
Study Completion Date
March 10, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Pamukkale University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.
Detailed Description
Parkinson's Disease (PD), first described by James Parkinson in 1817, is a progressive movement disorder that develops mainly as a result of the destruction of nigrostriatal dopaminergic neurons. Involvement of nigrostriatal dopaminergic neurons is associated with the motor manifestations of the disease. The most common of these symptoms are; resting tremor, bradykinesia, rigidity and balance disorder. However, non-motor symptoms related to the involvement of nervous system structures other than the dopaminergic nigrostriatal system can be observed in PD. However, due to the predominance of motor symptoms in PD, it took many years to notice cognitive changes. Traditionally, cognitive impairments in PD have been expected to occur in the advanced stages of the disease. However, cognitive impairments in the early stages are reported in approximately 30-35% of patients. Cognitive dysfunction is defined in PD, ranging from mild impairments in certain cognitive domains to severe dementia. Cognitive impairment primarily affects executive and visuospatial functions, and memory is secondarily affected.
Executive functions are higher cognitive processes that use and modify information from many cortical sensory systems in the fore and hindbrain areas to modulate and teach behavior. The frontal cortex, especially the prefrontal cortex and its striatal connections are very important neuroanatomical regions for executive functions. The relationship between the effects of cognition and motor performance and parameters in groups such as the elderly, PD and Alzheimer's patients in which these centers are affected has been an issue that has attracted the attention of many researchers. Most of the studies have focused on the lower extremity performance of cognition. However , it has been reported that cognition has positive effects on upper extremity performance and early acquired upper extremity skills have positive effects on cognitive performance .
The aim of our study is to determine the effect of cognitive functions on upper extremity functionality in individuals with Parkinson's Disease.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson, Cognitive Impairment, Upper Extremity Problem, Functional Disturbance
Keywords
Parkinson, Cognitive function, Upper extremity
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
patient and age-gender matched healthy groups
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
104 (Actual)
8. Arms, Groups, and Interventions
Arm Title
patient group
Arm Type
Experimental
Arm Description
parkınson patient group
Arm Title
healthy group
Arm Type
Other
Arm Description
age-gender matched healthy group
Intervention Type
Diagnostic Test
Intervention Name(s)
clinical assessment
Other Intervention Name(s)
modifiye hoehn yahr
Intervention Description
clinical staging
Primary Outcome Measure Information:
Title
Modified Hoehn Yahr Scale
Description
Used for clinical staging of Parkinson's disease
Time Frame
1 year
Title
Unified Parkinson's Disease Rating Scale
Description
Used for the evaluation of clinical manifestations of Parkinson's disease
Time Frame
1 year
Title
Parkinson's Disease Questionnaire-PDQ 39
Description
Used to assess the quality of life of Parkinson's patients
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Stroop Test
Description
measures the selective attention ability of individuals
Time Frame
1 year
Title
Wechsler Memory Scale-Revised
Description
To assess attention, learning, memory and working memory in individuals aged 16-89
Time Frame
1 year
Title
Dexterity Questionnaire-24
Description
To assess manuel dexterity
Time Frame
1 year
Title
Nine Hole Peg Test
Description
To assess manuel dexterity
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Having a diagnosis of Parkinson's Disease.
Not having hearing and vision problems.
To be able to take the commands required for the manual dexterity tests.
Agree to participate in the study.
Exclusion Criteria:
Having undergone musculoskeletal surgery for the upper extremity.
Having vision and hearing problems.
Having an additional disease that may affect cognitive tests.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
DUDU ŞIMŞEK
Organizational Affiliation
PhD student
Official's Role
Study Chair
Facility Information:
Facility Name
Pamukkale Unıversity
City
Denizli
ZIP/Postal Code
20000
Country
Turkey
12. IPD Sharing Statement
Learn more about this trial
The Effect of Cognitive Functions on Upper Extremity Functionality in Parkinson's Patients
We'll reach out to this number within 24 hrs